Novo, Lilly Weight-Loss Drugs Reduce Risk of Alzheimer’s, Study Shows. What It Means for the Stocks.
Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed. The ...
Verywell Health on MSN7d
What's New in Alzheimer's Treatment?
We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...
Bloomberg on MSN10d
Alzheimer’s drugs eyed as next big obesity-like opportunity
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Neurology Advisor3d
Certain Drug Types Associated With Risk for Dementia
Antimicrobials, vaccines, and anti-inflammatories are associated with a reduced risk for Alzheimer disease and dementia.
verywellhealth7d
What's Next for Alzheimer's Treatment? Some Scientists Are Betting on GLP-1 Drugs
Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...
biznews.com10d
🔒 FT: Weight-loss drugs reduce risk of Alzheimer’s, large study shows
A study shows GLP-1 weight-loss drugs reduce Alzheimer’s risk but increase arthritis, kidney, and pancreas issues.
Eli Lilly & Co’s Promising Growth: Accelerated Revenue and Drug Pipeline Advances
DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...
AOL12d
Eli Lilly Missed Sales Expectations Again. Should Investors Be Worried?
The Food and Drug Administration (FDA ... but sales of this treatment could grow past $2 billion annually in a few years. Last July, Lilly's Alzheimer's disease candidate Kisunla earned approval from ...
FiercePharma9d
Large study of Novo, Lilly weight loss drugs shows decrease in risk of Alzheimer's
As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...